Trial Outcomes & Findings for Safety and Performance of MICRORAPTOR™ Suture Anchors in Shoulder and Hip (NCT NCT03985839)

NCT ID: NCT03985839

Last Updated: 2026-07-13

Results Overview

Repair failure at 6 months was determined by physician diagnosis of recurrent shoulder dislocation, subluxation, and patient symptoms (e.g., pain). In the event of suspected repair failure, MRI or CT scan must confirm the root cause (i.e., intraarticular labrum failure or fixation repair failure) and assess glenoid bone loss. The repair failure rate was defined as the number of participants with confirmed repair failure divided by the total number of participants in the study device group at the 6-month follow-up.

Recruitment status

COMPLETED

Target enrollment

298 participants

Primary outcome timeframe

6 months

Results posted on

2026-07-13

Participant Flow

One Participant was excluded because the study device could not be used intraoperatively due to anchor failure.

Participant milestones

Participant milestones
Measure
MICRORAPTOR™ REGENESORB™ Suture Anchor
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless PEEK Suture Anchor
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
Overall Study
STARTED
114
122
61
Overall Study
COMPLETED
79
75
43
Overall Study
NOT COMPLETED
35
47
18

Reasons for withdrawal

Reasons for withdrawal
Measure
MICRORAPTOR™ REGENESORB™ Suture Anchor
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless PEEK Suture Anchor
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
Overall Study
Lost to Follow-up
28
35
14
Overall Study
Adverse Event
2
1
0
Overall Study
Physician Decision
1
2
1
Overall Study
Withdrawal by Subject
2
8
2
Overall Study
Non-compliance with Follow-up Visits
1
0
0
Overall Study
Subject Relocated
0
0
1
Overall Study
Device Deficiency
1
0
0
Overall Study
Follow-up Visit Missed and Could Not be Rescheduled
0
1
0

Baseline Characteristics

Safety and Performance of MICRORAPTOR™ Suture Anchors in Shoulder and Hip

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=114 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=122 Participants
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=61 Participants
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
Total
n=297 Participants
Total of all reporting groups
Age, Continuous
40.80 years
STANDARD_DEVIATION 13.64 • n=20 Participants
41.88 years
STANDARD_DEVIATION 14.94 • n=20 Participants
40.16 years
STANDARD_DEVIATION 15.17 • n=40 Participants
41.12 years
STANDARD_DEVIATION 14.44 • n=5 Participants
Sex: Female, Male
Female
68 Participants
n=20 Participants
65 Participants
n=20 Participants
32 Participants
n=40 Participants
165 Participants
n=5 Participants
Sex: Female, Male
Male
46 Participants
n=20 Participants
57 Participants
n=20 Participants
29 Participants
n=40 Participants
132 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
6 Participants
n=20 Participants
5 Participants
n=20 Participants
6 Participants
n=40 Participants
17 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
99 Participants
n=20 Participants
115 Participants
n=20 Participants
55 Participants
n=40 Participants
269 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
9 Participants
n=20 Participants
2 Participants
n=20 Participants
0 Participants
n=40 Participants
11 Participants
n=5 Participants
Region of Enrollment
United States
114 Participants
n=20 Participants
122 Participants
n=20 Participants
61 Participants
n=40 Participants
297 Participants
n=5 Participants
Body Mass Index (BMI)
26.44 kg/m^2
STANDARD_DEVIATION 4.85 • n=20 Participants
28.63 kg/m^2
STANDARD_DEVIATION 5.67 • n=20 Participants
27.32 kg/m^2
STANDARD_DEVIATION 5.05 • n=40 Participants
27.52 kg/m^2
STANDARD_DEVIATION 5.31 • n=5 Participants

PRIMARY outcome

Timeframe: 6 months

Population: The Safety (SAF) Population included all participants that received the specified study device with data collected for the outcome and time frame indicated.

Repair failure at 6 months was determined by physician diagnosis of recurrent shoulder dislocation, subluxation, and patient symptoms (e.g., pain). In the event of suspected repair failure, MRI or CT scan must confirm the root cause (i.e., intraarticular labrum failure or fixation repair failure) and assess glenoid bone loss. The repair failure rate was defined as the number of participants with confirmed repair failure divided by the total number of participants in the study device group at the 6-month follow-up.

Outcome measures

Outcome measures
Measure
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=108 Participants
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=84 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=44 Participants
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
Repair Failure Rate at 6 Months
0.93 proportion of participants
0 proportion of participants
Interval 95.7 to 100.0
0 proportion of participants

SECONDARY outcome

Timeframe: 12 months

Population: The Safety (SAF) Population included all participants that received the specified study device with data collected for the outcome and time frame indicated.

Repair failure at 12 months was determined by physician diagnosis of recurrent shoulder dislocation, subluxation, and patient symptoms (e.g., pain). In the event of suspected repair failure, MRI or CT scan must confirm the root cause (i.e., intraarticular labrum failure or fixation repair failure) and assess glenoid bone loss. The repair failure rate was defined as the number of participants with confirmed repair failure divided by the total number of participants in the study device group at the 12-month follow-up.

Outcome measures

Outcome measures
Measure
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=91 Participants
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=84 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=43 Participants
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
Repair Failure Rate at 12 Months
0 proportion of participants
0 proportion of participants
0 proportion of participants

SECONDARY outcome

Timeframe: Baseline to 6 months, 12 months, and 24 months

Population: The Full Analysis Set (FAS) Population included all participants enrolled into the study and had at least one post-baseline visit with data collected for the outcome and time frame indicated. Only the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor group had a 24-month visit (i.e., MICRORAPTOR™ REGENESORB™ Suture Anchor and MICRORAPTOR™ Knotless PEEK Suture Anchor only conducted 6-month and 12-month visits).

Pain was assessed using a Visual Analogue Scale (VAS) where participants indicated their pain level by marking a point that represented their perceived pain intensity. Scores ranged from 0 to 100, with 0 representing no pain and 100 representing the worst imaginable pain (i.e., a worse outcome). A decrease in VAS Pain score indicated a reduction in pain (i.e., a better outcome) and an increase indicated worsening in pain (i.e., a worse outcome). The mean change in pain score was recorded on the VAS from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.

Outcome measures

Outcome measures
Measure
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=104 Participants
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=82 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=44 Participants
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
Visual Analogue Scale (VAS) Pain Change From Baseline
Baseline to 6 months
-31.17 score on a scale
Standard Deviation 27.39
-35.02 score on a scale
Standard Deviation 30.02
-30.61 score on a scale
Standard Deviation 24.75
Visual Analogue Scale (VAS) Pain Change From Baseline
Baseline to 12 months
-33.91 score on a scale
Standard Deviation 29.68
-36.22 score on a scale
Standard Deviation 28.10
-28.14 score on a scale
Standard Deviation 27.81
Visual Analogue Scale (VAS) Pain Change From Baseline
Baseline to 24 months
-35.54 score on a scale
Standard Deviation 29.28

SECONDARY outcome

Timeframe: 24 months

Population: The Safety (SAF) Population included all participants that received the specified study device with data collected for the outcome and time frame indicated.

Repair failure at 24 months was collected only for participants that received the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor. Repair failure was determined by physician diagnosis of recurrent shoulder dislocation, subluxation, and patient symptoms (e.g., pain). In the event of suspected repair failure, MRI or CT scan must confirm the root cause (i.e., intraarticular labrum failure or fixation repair failure) and assess glenoid bone loss. The repair failure rate was defined as the number of participants with confirmed repair failure divided by the total number of participants in the study device group at the 24-month follow-up.

Outcome measures

Outcome measures
Measure
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=75 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless PEEK Suture Anchor
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
Repair Failure Rate at 24 Months (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY)
0 proportion of participants

SECONDARY outcome

Timeframe: Baseline, 6 months, and 24 months

Population: The Full Analysis Set (FAS) Population included participants enrolled into the study that had at least one post-baseline visit with data collected for the outcome, time frame, and treatment group indicated. Participants with discrepancies in MRI and case report form (CRF) data were excluded from analysis. Due to these inconsistencies, only participants with matching MRI and CRF data were analyzed.

Hip Magnetic Resonance Imagining (MRI) was performed on participants that received the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor to determine anchor absorption/replacement by bone at baseline, 6 months, and 24 months based on acetabular labral condition classification. The number of participants acetabular labral condition was classified as one of the following: * Normal Intact Labrum * Labral Tear / Degeneration

Outcome measures

Outcome measures
Measure
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=45 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless PEEK Suture Anchor
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Acetabular Labral Condition
Baseline · Normal Intact Labrum
5 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Acetabular Labral Condition
Baseline · Labral Tear / Degeneration
32 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Acetabular Labral Condition
6 months · Normal Intact Labrum
3 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Acetabular Labral Condition
6 months · Labral Tear / Degeneration
42 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Acetabular Labral Condition
24 months · Normal Intact Labrum
13 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Acetabular Labral Condition
24 months · Labral Tear / Degeneration
16 Participants

SECONDARY outcome

Timeframe: Baseline, 6 months, and 24 months

Population: The Full Analysis Set (FAS) Population included participants enrolled into the study that had at least one post-baseline visit with data collected for the outcome, time frame, and treatment group indicated. Participants with discrepancies in MRI and case report form (CRF) data were excluded from analysis. Due to these inconsistencies, only participants with matching MRI and CRF data were analyzed.

Hip Magnetic Resonance Imagining (MRI) was performed on participants that received the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor to determine anchor absorption/replacement by bone at baseline, 6 months, and 24 months based on joint effusion classification. The number of participants joint effusion was classified as one of the following: * None * Mild * Moderate * Severe

Outcome measures

Outcome measures
Measure
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=10 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless PEEK Suture Anchor
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
Baseline · Severe
0 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
6 months · None
5 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
6 months · Mild
5 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
6 months · Moderate
0 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
6 months · Severe
0 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
24 months · None
3 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
24 months · Mild
3 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
24 months · Moderate
0 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
24 months · Severe
0 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
Baseline · None
9 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
Baseline · Mild
0 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
Baseline · Moderate
1 Participants

SECONDARY outcome

Timeframe: Baseline, 6 months, and 24 months

Population: The Full Analysis Set (FAS) Population included participants enrolled into the study that had at least one post-baseline visit with data collected for the outcome, time frame, and treatment group indicated. Participants with discrepancies in MRI and case report form (CRF) data were excluded from analysis. Due to these inconsistencies, only participants with matching MRI and CRF data were analyzed.

Hip Magnetic Resonance Imagining (MRI) was performed on participants that received the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor to determine anchor absorption/replacement by bone at baseline, 6 months, and 24 months based on the presence of bone marrow edema. The number of participants with bone marrow edema were categorized as 'Absent' or 'Present'.

Outcome measures

Outcome measures
Measure
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=10 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless PEEK Suture Anchor
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Bone Marrow Edema
Baseline · Absent
9 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Bone Marrow Edema
Baseline · Present
1 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Bone Marrow Edema
6 months · Absent
5 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Bone Marrow Edema
6 months · Present
5 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Bone Marrow Edema
24 months · Absent
4 Participants
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Bone Marrow Edema
24 months · Present
1 Participants

SECONDARY outcome

Timeframe: Baseline to 6 months, 12 months, and 24 months

Population: The Full Analysis Set (FAS) Population included all shoulder participants enrolled into the study and had at least one post-baseline visit with data collected for the outcome and time frame indicated. Only the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor group had a 24-month visit (i.e., MICRORAPTOR™ REGENESORB™ Suture Anchor and MICRORAPTOR™ Knotless PEEK Suture Anchor only conducted 6-month and 12-month visits).

The Rowe shoulder score for shoulder instability evaluated using a 3-item instrument completed by the investigator or qualified, delegated study staff. Its questions addressed the categories of shoulder stability (0 to 50 points), motion (0 to 20 points), and function (0 to 30 points). Scores ranged from 0 to 100 with a score of 90-100 points indicating an excellent evaluation, 75-89 points indicating a good evaluation, 51-74 points indicating a fair evaluation, and =\< 50 points indicating a poor evaluation. An increase in Rowe score indicated reduced shoulder instability (i.e., a better outcome) and a decrease indicated worsening instability (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.

Outcome measures

Outcome measures
Measure
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=50 Participants
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=35 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=19 Participants
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
Rowe Shoulder Score Change From Baseline (Shoulder Participants ONLY)
Baseline to 6 months
40.0 score on a scale
Standard Deviation 21.17
30.43 score on a scale
Standard Deviation 21.40
37.5 score on a scale
Standard Deviation 20.82
Rowe Shoulder Score Change From Baseline (Shoulder Participants ONLY)
Baseline to 12 months
43.05 score on a scale
Standard Deviation 21.06
34.43 score on a scale
Standard Deviation 22.06
44.74 score on a scale
Standard Deviation 28.26
Rowe Shoulder Score Change From Baseline (Shoulder Participants ONLY)
Baseline to 24 months
48.64 score on a scale
Standard Deviation 18.93

SECONDARY outcome

Timeframe: Baseline to 6 months, 12 months, and 24 months

Population: The Full Analysis Set (FAS) Population included all shoulder participants enrolled into the study that had at least one post-baseline visit with data collected for the outcome and time frame indicated. Only the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor group had a 24-month visit (i.e., MICRORAPTOR™ REGENESORB™ Suture Anchor and MICRORAPTOR™ Knotless PEEK Suture Anchor only conducted 6-month and 12-month visits).

Western Ontario Shoulder Instability Index (WOSI) was a participant completed instrument. Its categories included "physical symptoms", "sports, recreation, work", "pain", "lifestyle", and "emotion", with questions within each category scored from 0 to 100 using a visual analog scale. Scores were combined to produce an overall score that ranged from 0 to 2100 with a score of 0 indicating better shoulder function and 2100 indicating worse shoulder function. A decrease in WOSI score indicated improving shoulder function (i.e., a better outcome) and an increase indicated worsening shoulder function (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.

Outcome measures

Outcome measures
Measure
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=49 Participants
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=35 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=18 Participants
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
Western Ontario Shoulder Instability Index (WOSI) Score Change From Baseline (Shoulder Participants ONLY)
Baseline to 6 months
-792.94 score on a scale
Standard Deviation 505.37
-925.68 score on a scale
Standard Deviation 500.71
-719.44 score on a scale
Standard Deviation 393.45
Western Ontario Shoulder Instability Index (WOSI) Score Change From Baseline (Shoulder Participants ONLY)
Baseline to 12 months
-989.85 score on a scale
Standard Deviation 483.85
-988.43 score on a scale
Standard Deviation 453.91
-927.06 score on a scale
Standard Deviation 511.32
Western Ontario Shoulder Instability Index (WOSI) Score Change From Baseline (Shoulder Participants ONLY)
Baseline to 24 months
-1110.03 score on a scale
Standard Deviation 447.06

SECONDARY outcome

Timeframe: Baseline to 6 months, 12 months, and 24 months

Population: The Full Analysis Set (FAS) Population included all shoulder participants enrolled into the study that had at least one post-baseline visit with data collected for the outcome and time frame indicated. Only the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor group had a 24-month visit (i.e., MICRORAPTOR™ REGENESORB™ Suture Anchor and MICRORAPTOR™ Knotless PEEK Suture Anchor only conducted 6-month and 12-month visits).

Constant-Murley Shoulder (CMS) scale assesses four aspects related to shoulder pathology: pain, activities of daily living (ADL), range of motion (ROM), and strength. The total score ranged from 0 to 100, with a higher score indicating better shoulder function. An increase in CMS score indicated improving shoulder function (i.e., a better outcome) and a decrease indicated worsening function (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.

Outcome measures

Outcome measures
Measure
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=43 Participants
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=29 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=19 Participants
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
Constant-Murley Shoulder Scale Change From Baseline (Should Participants ONLY)
Baseline to 6 months
23.60 score on a scale
Standard Deviation 24.78
26.11 score on a scale
Standard Deviation 19.07
17.14 score on a scale
Standard Deviation 25.98
Constant-Murley Shoulder Scale Change From Baseline (Should Participants ONLY)
Baseline to 12 months
29.78 score on a scale
Standard Deviation 20.47
32.31 score on a scale
Standard Deviation 12.91
30.18 score on a scale
Standard Deviation 25.85
Constant-Murley Shoulder Scale Change From Baseline (Should Participants ONLY)
Baseline to 24 months
38.53 score on a scale
Standard Deviation 22.26

SECONDARY outcome

Timeframe: Baseline to 6 months, 12 months, and 24 months

Population: The Full Analysis Set (FAS) Population included all hip participants enrolled into the study that had at least one post-baseline visit with data collected for the outcome and time frame indicated. Only the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor group had a 24-month visit (i.e., MICRORAPTOR™ REGENESORB™ Suture Anchor and MICRORAPTOR™ Knotless PEEK Suture Anchor only conducted 6-month and 12-month visits).

The Hip Outcome Score Activities of Daily Living (HOS-ADL) subscale consisted of 17 items that addressed specific activities related to hip function. Scores ranged from 0 to 100 with 0 representing the least function and 100 representing the most function. An increase in HOS-ADL score indicated improved hip function (i.e., a better outcome) and a decrease indicated worsening function (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.

Outcome measures

Outcome measures
Measure
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=38 Participants
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=37 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=17 Participants
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
Hip Outcome Score Activities of Daily Living (HOS-ADL) Score Change in Baseline (Hip Participants ONLY)
Baseline to 6 months
26.20 score on a scale
Standard Deviation 16.93
20.03 score on a scale
Standard Deviation 16.29
21.11 score on a scale
Standard Deviation 14.44
Hip Outcome Score Activities of Daily Living (HOS-ADL) Score Change in Baseline (Hip Participants ONLY)
Baseline to 12 months
25.91 score on a scale
Standard Deviation 18.50
22.19 score on a scale
Standard Deviation 16.88
23.00 score on a scale
Standard Deviation 13.20
Hip Outcome Score Activities of Daily Living (HOS-ADL) Score Change in Baseline (Hip Participants ONLY)
Baseline to 24 months
25.95 score on a scale
Standard Deviation 16.71

SECONDARY outcome

Timeframe: Baseline to 6 months, 12 months, and 24 months

Population: The Full Analysis Set (FAS) Population included all hip participants enrolled into the study that had at least one post-baseline visit with data collected for the outcome and time frame indicated. Only the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor group had a 24-month visit (i.e., MICRORAPTOR™ REGENESORB™ Suture Anchor and MICRORAPTOR™ Knotless PEEK Suture Anchor only conducted 6-month and 12-month visits).

Modified Harris Hip Score (mHHS) is a joint specific score covering domains of pain, function, functional activities, absence of deformity, and hip range of motion. Scores ranged from 0 to 100, with 0 representing worse disability and 100 representing less disability. An increase in mHHS indicated improved hip joint function (i.e., a better outcome) and a decrease indicated worsening function (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.

Outcome measures

Outcome measures
Measure
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=52 Participants
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=47 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=28 Participants
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
Modified Harris Hip Score (mHHS) Change From Baseline (Hip Participants ONLY)
Baseline to 6 months
25.88 score on a scale
Standard Deviation 19.56
17.28 score on a scale
Standard Deviation 17.23
21.54 score on a scale
Standard Deviation 15.76
Modified Harris Hip Score (mHHS) Change From Baseline (Hip Participants ONLY)
Baseline to 12 months
24.56 score on a scale
Standard Deviation 17.40
23.60 score on a scale
Standard Deviation 17.50
17.79 score on a scale
Standard Deviation 14.35
Modified Harris Hip Score (mHHS) Change From Baseline (Hip Participants ONLY)
Baseline to 24 months
25.05 score on a scale
Standard Deviation 19.01

Adverse Events

MICRORAPTOR™ REGENESORB™ Suture Anchor

Serious events: 6 serious events
Other events: 37 other events
Deaths: 0 deaths

MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor

Serious events: 7 serious events
Other events: 35 other events
Deaths: 0 deaths

MICRORAPTOR™ Knotless PEEK Suture Anchor

Serious events: 2 serious events
Other events: 13 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=114 participants at risk
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=122 participants at risk
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=61 participants at risk
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
Cardiac disorders
ISCHEMIC HEART DISEASE
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Gastrointestinal disorders
UNSPECIFIED GASTROINTESTINAL PROBLEM
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Musculoskeletal and connective tissue disorders
ARTHRITIS
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Musculoskeletal and connective tissue disorders
ANKYLOSIS
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Musculoskeletal and connective tissue disorders
MUSCLE/TENDON DAMAGE
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Musculoskeletal and connective tissue disorders
OSSIFICATION
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Musculoskeletal and connective tissue disorders
UNSPECIFIED MUSCULOSKELETAL PROBLEM
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Skin and subcutaneous tissue disorders
CELLULITIS
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
1.6%
2/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Injury, poisoning and procedural complications
IMPLANT PAIN
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Injury, poisoning and procedural complications
INADEQUATE PAIN RELIEF
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
General disorders
HERNIA
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
General disorders
PAIN
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).

Other adverse events

Other adverse events
Measure
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=114 participants at risk
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=122 participants at risk
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=61 participants at risk
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
General disorders
HEADACHE
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Nervous system disorders
NERVE DAMAGE
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Nervous system disorders
NEURALGIA
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Nervous system disorders
NUMBNESS
1.8%
2/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Immune system disorders
HYPERSENSITIVITY/ALLERGIC REACTION
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
1.6%
2/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Cardiac disorders
PERICARDITIS
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Respiratory, thoracic and mediastinal disorders
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Respiratory, thoracic and mediastinal disorders
PULMONARY EMPHYSEMA
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Respiratory, thoracic and mediastinal disorders
RESPIRATORY TRACT INFECTION
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Eye disorders
UNSPECIFIED EYE / VISION PROBLEM
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Gastrointestinal disorders
NAUSEA
2.6%
3/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Gastrointestinal disorders
UNSPECIFIED GASTROINTESTINAL PROBLEM
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Renal and urinary disorders
MICTURITION URGENCY
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Renal and urinary disorders
URINARY RETENTION
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Musculoskeletal and connective tissue disorders
ARTHRALGIA
1.8%
2/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Musculoskeletal and connective tissue disorders
BONE FRACTURE(S)
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
3.3%
2/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Musculoskeletal and connective tissue disorders
CRAMP(S) /MUSCLE SPASM(S)
1.8%
2/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Injury, poisoning and procedural complications
DAMAGE TO LIGAMENT(S)
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Musculoskeletal and connective tissue disorders
JOINT DISLOCATION
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Musculoskeletal and connective tissue disorders
LOSS OF RANGE OF MOTION
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
2.5%
3/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Musculoskeletal and connective tissue disorders
MUSCLE/TENDON DAMAGE
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
1.6%
2/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
General disorders
NECK PAIN
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Musculoskeletal and connective tissue disorders
OSSIFICATION
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Injury, poisoning and procedural complications
TOOTH FRACTURE
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Musculoskeletal and connective tissue disorders
UNSPECIFIED MUSCULOSKELETAL PROBLEM
4.4%
5/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Infections and infestations
ABSCESS
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Skin and subcutaneous tissue disorders
URTICARIA
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
CYST(S)
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Infections and infestations
VIRAL INFECTION
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Injury, poisoning and procedural complications
FALL
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Injury, poisoning and procedural complications
UNSPECIFIED TISSUE INJURY
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Injury, poisoning and procedural complications
IMPLANT PAIN
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
Investigations
LOW OXYGEN SATURATION
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
General disorders
INFLAMMATION
2.6%
3/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
1.6%
2/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
General disorders
PAIN
9.6%
11/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
8.2%
10/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
3.3%
2/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
General disorders
CHEST PAIN
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
General disorders
SWELLING/ EDEMA
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).

Additional Information

Senior Manager Clinical Compliance

Smith+Nephew, Inc

Phone: 1-800-821-5700

Results disclosure agreements

  • Principal investigator is a sponsor employee The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period up to 90 days but less than or equal to 180 days from the time submitted to the sponsor for review. Sponsor may delay publication up to 180 days to permit the filing of appropriate patent applications if the sponsor believes any publication contains any information relating to patentable items and cannot extend the embargo.
  • Publication restrictions are in place

Restriction type: OTHER